Mainz Biomed (MYNZ) announced that its partner, GANZIMMUN Diagnostics, has officially launched the enhanced ColoAlert colorectal cancer screening test. Starting this January, patients across Germany can access this new version of the Company’s screening test, in time for Colorectal Cancer Awareness Month in March. First introduced by Mainz Biomed in mid-2024, the enhanced ColoAlert features advancements, including a proprietary DNA stabilizing buffer, to deliver accurate results even with varying sample volumes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ: